Reunion Neuroscience and Seleni Institute Collaborate on Maternal Mental Health Diagnostics and Treatment

Reunion Neuroscience Inc., a company in the clinical stage of biopharmaceutical development, is taking significant steps to transform the treatment of mental health disorders, particularly those that are currently underserved. The company has recently announced a partnership with the Seleni Institute, a nonprofit organization based in New York City dedicated to addressing maternal mental health and wellness issues through treatment and training.

This collaboration will provide healthcare professionals with access to the Seleni Institute’s extensive, evidence-based training programs focusing on maternal mental health conditions. These programs cover perinatal mood and anxiety disorders (PMADs), perinatal grief, and postpartum depression (PPD), offering expert guidance on the diagnosis and treatment of these conditions.

Greg Mayes, the President and CEO of Reunion Neuroscience, emphasized the importance of addressing maternal mental health issues, which impact one in five women during or after pregnancy. He stated that the partnership with the Seleni Institute would help ensure that healthcare professionals have access to crucial educational resources to improve the diagnosis and treatment of these disorders. Additionally, Mayes highlighted the ongoing support for the maternal mental health community through their Phase 2 RECONNECT trial, which evaluates their lead candidate, RE104, in women with moderate-to-severe PPD.

The RECONNECT Phase 2 clinical trial is a multicenter, randomized, double-blind study designed to assess the safety and efficacy of a single subcutaneous dose of RE104 in adult women with moderate-to-severe postpartum depression. For more details about the study and eligibility for enrollment, interested parties can visit the study’s website.

Seema Bajaj, the Executive Director of the Seleni Institute, expressed excitement about the partnership with Reunion Neuroscience. She noted that this collaboration aligns with their mission to support and improve maternal mental health. The sponsorship from Reunion will aid in providing healthcare providers with essential training materials, thereby enhancing their ability to address critical issues such as PPD effectively. Bajaj also highlighted the ongoing efforts to raise awareness and reduce the stigma surrounding reproductive and maternal mental health conditions.

The Seleni Institute, founded in 2011, has been a pioneer in advancing maternal mental health. The institute has trained over 6,200 professionals across 30 countries and positively impacted more than 10 million lives globally. Seleni offers a hybrid approach that includes clinical services for individuals, couples, and families, as well as accredited training for healthcare providers.

Reunion Neuroscience is committed to advancing psychedelic therapeutic solutions to treat various mental health disorders. The company became private in August 2023 and completed a Series A financing in May 2024, co-led by MPM BioImpact and Novo Holdings. Reunion’s current focus is on investigating RE104 for postpartum depression and exploring additional neuropsychiatric indications, such as adjustment disorders in patients with mental illnesses like cancer, where traditional treatments fall short.

The Seleni Institute is renowned for its efforts in maternal and reproductive mental health, offering specialized therapy and training to support individuals, couples, and families through various reproductive life challenges. Established by George and Nitzia Logothetis, Seleni has significantly improved over 10 million lives globally.

This partnership between Reunion Neuroscience and the Seleni Institute represents a crucial step towards enhancing the understanding and treatment of maternal mental health issues, ultimately aiming to provide better support for affected women worldwide.